Abstract
Ocular surface condition has a major impact on glaucoma treatment. Healthy ocular surface provides a favorable environment for antiglaucomatous eye drops efficacy. Ocular surface condition strongly relies on the ocular tear film, cellular arrangement of the cornea and the interfaces between the surfaces. Comprehensive collection of medical history, as well as detailed ocular surface examination under slit lamp and dry eye tests are highly recommended prior to glaucoma medical treatment. Treating the underlying condition must be started before or together with antiglaucomatous treatment.
Finding a perfect topical drug for glaucoma patients can be a challenging task. A perfect drug must not only be sufficiently effective, but also tolerated well by the patient. Evaluating antiglaucomatous drugs’ effects to ocular surface, three major factors must be considered: ocular surface toxicity, inflammation and allergy. Antiglaucomatous medications’ preservatives are also responsible for a vast amount of adverse effects.
Glaucoma is a life-time diagnosis, which requires IOP lowering treatment on a daily basis. Sometimes the target IOP is not achieved, so the surgical treatment is performed. Patients with healthy ocular surface have a higher chance for successful surgery, than patients with ocular surface damage.
Preserving healthy ocular surface during medical glaucoma treatment is not only important due to subjective patient discomfort, but also for patient compliance and long term treatment results, including surgical treatment and maintaining vision.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Willcox MDP, Argüeso P, Georgiev GA, Holopainen JM, Laurie GW, Millar TJ, Papas EB, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017;15(3):366–403. https://doi.org/10.1016/j.jtos.2017.03.006.
Mishima S, Maurice DM. The oily layer of the tear film and evaporation from the corneal surface. Exp Eye Res. 1961;1(1):39–45. https://doi.org/10.1016/S0014-4835(61)80006-7.
King-Smith PE, Fink BA, Hill RM, Koelling KW, Tiffany JM. The thickness of the tear film. Curr Eye Res. 2004;29(4–5):357–68. https://doi.org/10.1080/02713680490516099.
Cho P, Brown B. Disruption of the tear film by the application of small drops of saline and surfactant. Cont Lens Anterior Eye. 1998;21(3):73–80. https://doi.org/10.1016/S1367-0484(98)80026-X.
Wizert A, Iskander DR, Cwiklik L. Organization of lipids in the tear film: a molecular-level view. PLoS One. 2014;9(3). https://doi.org/10.1371/journal.pone.0092461.
Telenius J, Koivuniemi A, Kulovesi P, Holopainen JM, Vattulainen I. Role of neutral lipids in tear fluid lipid layer: Coarse-Grained Simulation Study. Langmuir. 2012;28(49):17092–100. https://doi.org/10.1021/la304366d.
King-Smith PE, Erich AH, Jason JN. Application of a novel interferometric method to investigate the relation between lipid layer thickness and tear film thinning. Invest Ophthalmol Vis Sci. 2010;51(5):2418–23. https://doi.org/10.1167/iovs.09-4387.
Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci. 1997;74(1):8–13. https://doi.org/10.1097/00006324-199.701.000-00014.
Dartt DA. Tear Lipocalin: structure and function. Ocul Surf. 2011;9:126–38. http://www.ncbi.nlm.nih.gov/pubmed/21791187
Mort RL, Douvaras P, Morley SD, Dorà N, Hill RE, Martin Collinson J, West JD. Stem cells and corneal epithelial maintenance–insights from the mouse and other animal models. Mouse Dev. 2012;55:357–94. https://doi.org/10.1007/978-3-642-30,406-4.
Majo F, Rochat A, Nicolas M, Jaoudé GA, Barrandon Y. Oligopotent stem cells are distributed throughout the mammalian ocular surface. Nature. 2008;456(7219):250–4. https://doi.org/10.1038/nature07406.
Ban Y, Dota A, Cooper LJ, Fullwood NJ, Nakamura T, Tsuzuki M, Mochida C, Kinoshita S. Tight junction-related protein expression and distribution in human corneal epithelium. Exp Eye Res. 2003;76(6):663–9. https://doi.org/10.1016/S0014-4835(03)00054-X.
Mantelli F, Mauris J, Argüeso P. The ocular surface epithelial barrier and other mechanisms of mucosal protection: from allergy to infectious diseases. Curr Opin Allergy Clin Immunol. 2013;13(5):563–8. https://doi.org/10.1097/ACI.0b013e3283645899.
Hashimoto Y, Yokoo S, Usui T, Tsubota Y, Yamagami S. High permeability and intercellular space widening with brimonidine tartrate eye drops in cultured stratified human corneal epithelial sheets. Cornea. 2017;37(2):242–7. https://doi.org/10.1097/ICO.0000000000001450.
Chen H. Recent developments in ocular drug delivery. J Drug Target. 2015;23(7–8):597–604. https://doi.org/10.3109/1061186X.2015.1052073.
Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, Lockwood A. Principles of pharmacology in the eye. Br J Pharmacol. 2017;174(23):4205–23. https://doi.org/10.1111/bph.14024.
Gupta R, Patil B, Shah BM, Bali SJ, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21(3):189–92. https://doi.org/10.1097/IJG.0b013e31820bd2e1.
Portes AJF, Lopes RMG, Cardoso MG, Fernandes RA, Souza TA, Portes AJF, Lopes RMG, Cardoso MG, Fernandes RA, Souza TA. Self instillation perception of eye drops in elderly patients with and without facial support device. Rev Bras Oftalmol. 2016;75(6):447–51. Sociedade Brasileira de Oftalmologia. https://doi.org/10.5935/0034-7280.20160090.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Pakuliene, G. (2019). Ocular Surface Anatomy and Physiology. In: Januleviciene, I., Harris, A. (eds) Biophysical Properties in Glaucoma. Springer, Cham. https://doi.org/10.1007/978-3-319-98198-7_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-98198-7_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-98197-0
Online ISBN: 978-3-319-98198-7
eBook Packages: MedicineMedicine (R0)